# S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

> **NCT00087152** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00087152
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087152, "S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00087152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*